Corbus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon from LifeSci Capital maintained a Buy rating on the stock and has a $53.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oliver McCammon has given his Buy rating due to a combination of factors including the promising developments in Corbus Pharmaceuticals’ pipeline. Notably, the company has made significant progress with its CRB-701 program, which has shown a higher objective response rate (ORR) in heavily pretreated head and neck squamous cell carcinoma (HNSCC) patients compared to existing treatments. This positions CRB-701 as a strong candidate for future success, especially with plans to initiate a registrational trial by mid-2026.
Additionally, Corbus is advancing its CRB-913 program, a next-generation small molecule targeting obesity, with Phase 1 trials expected to complete by the end of 2025. The company’s strategic plans, coupled with a robust pipeline and a cash runway of approximately 2.5 years, support a positive outlook. These factors collectively underpin McCammon’s confidence in the company’s potential, leading to the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.